Abstract
Immunosuppressive therapies are critical in the management of numerous conditions including myasthenia gravis. Mycophenolate mofetil is a widely used, oral immunosuppressive agent that is considered to have few adverse effects compared with similar drugs. We report the case of a patient who developed T-cell lymphoproliferative lesions following long-term treatment with mycophenolate mofetil and prednisone for myasthenia gravis. The lesions resolved following cessation of the treatment. This case highlights a serious complication of a commonly used drug.
MeSH terms
-
Aged
-
Biomarkers / analysis
-
Epstein-Barr Virus Infections / chemically induced*
-
Epstein-Barr Virus Infections / immunology
-
Epstein-Barr Virus Infections / physiopathology
-
Female
-
Genitalia, Female / diagnostic imaging
-
Genitalia, Female / pathology
-
Gingiva / pathology
-
Gingivitis / chemically induced
-
Gingivitis / pathology
-
Humans
-
Immunosuppressive Agents / adverse effects*
-
Lymphoproliferative Disorders / chemically induced*
-
Lymphoproliferative Disorders / immunology
-
Lymphoproliferative Disorders / physiopathology
-
Mouth / diagnostic imaging
-
Mouth / pathology
-
Myasthenia Gravis / drug therapy*
-
Myasthenia Gravis / immunology
-
Myasthenia Gravis / physiopathology
-
Mycophenolic Acid / adverse effects
-
Mycophenolic Acid / analogs & derivatives*
-
Positron-Emission Tomography
-
Prednisone / therapeutic use
-
T-Lymphocytes / drug effects*
-
T-Lymphocytes / immunology
-
T-Lymphocytes / virology
Substances
-
Biomarkers
-
Immunosuppressive Agents
-
Mycophenolic Acid
-
Prednisone